Psychometric Evaluation of Two Scales Assessing Functional Status and Peripheral Neuropathy Associated With Chemotherapy for Ovarian Cancer: A Gynecologic Oncology Group Study

Lois Almadrones

Deborah B. McGuire

Janet Ruth Walczak

Colleen M. Florio

Chunqiao Tian

ONF 2004, 31(3), 615-623. DOI: 10.1188/04.ONF.615-623

Purpose/Objectives: To evaluate the psychometric properties of two adapted scales, one for functional status and one for peripheral neuropathy secondary to neurotoxic chemotherapy.

Design: Repeated measures methodologic design conducted within a Gynecologic Oncology Group (GOG) phase III clinical trial that randomly assigned patients with advanced epithelial ovarian cancer to cisplatin and cyclophosphamide or cisplatin and paclitaxel.

Setting: 8 GOG institutions participating in the GOG clinical trial.

Sample: 88 evaluable outpatients enrolled in the GOG clinical trial. Sample size at time 1 (T1) was 88 patients and at time 2 (T2) was 67 patients.

Methods: All scales were administered at T1 (prior to initiation of chemotherapy) and T2 (after six cycles of chemotherapy but prior to second-look laparotomy). Internal consistency reliability, criterion validity, and construct validity were evaluated, and clinical application was explored.

Main Research Variables: Self-reported peripheral neuropathy and functional status (comprised of physical function and role function subscales), the GOG performance status scale, and the GOG toxicity criteria.

Findings: Reliability coefficients at T1 were physical function = 0.83, role function = 0.96, and peripheral neuropathy = 0.91; at T2, they were physical function = 0.83, role function = 0.92, and peripheral neuropathy = 0.89. At T1, physical function and role function correlated positively with performance status. Peripheral neuropathy correlated positively with GOG toxicity criteria used at T2. Principal component factor analysis suggested that the functional status scale had a two-factor structure with factors representing general and specific mobility and that the peripheral neuropathy scale also had a two-factor structure with factors representing foot and hand neuropathy.

Conclusions: The physical function, role function, and peripheral neuropathy scales have internal consistency, reliability, criterion validity, and construct validity. However, revision of the scales should address modification of specific questions and consider increasing the Likert scale from a four-point to a five- or seven-point scale to enhance clinical sensitivity and application.

Implications for Nursing: With minor modifications, these scales should be useful in assessing physical function, role function, and peripheral neuropathy in patients who receive agents that may cause peripheral neuropathy.

Jump to a section


    Aaronson, N. (1989). Quality of life in clinical trials: Methodologic issues. Controlled Clinical Trials, 10(Suppl. 4), 195S-208S.

    Aaronson, N. (1990). Quality of life research in cancer clinical trials: A need for common rules and language. Oncology (Huntington), 4(5), 59-66.

    Aaronson, N., Ahmedzai, S., Bullinger, M., Crabeels, D., Estapé, J., Filiberti, A., et al., for the EORTC Study Group on Quality of Life. (1991). The EORTC core quality-of-life questionnaire: Interim results of an international field study. In D. Osoba (Ed.)Effect of cancer on quality of life (pp. 185-203). New York: Raven Press.

    Aaronson, N., Baker, W., Stewart, A., Van Dam, F., Zandwijik, N., Yarmold, J., et al. (1987). Multidimensional approach to the measurement of QOL in lung cancer clinical trials. In N. Aaronson & J. Beckman (Eds.)The quality of life of cancer patients (pp. 63-82). New York: Raven Press.

    Almadrones, L., & Arcot, R. (1999). Patient guide to peripheral neuropathy. Oncology Nursing Forum, 26, 1359-1360.

    Armstrong, T., Rust, D., & Kohtz, J. (1997). Neurologic, pulmonary, and cutaneous toxicities of high-dose chemotherapy. Oncology Nursing Forum, 24(Suppl. 1), 23-33.

    Blessing, J. (1990). Design, analysis and interpretation of chemotherapy trials in gynecologic cancer. In G. Deppe (Ed.)Chemotherapy of gynecologic cancer (2nd ed., pp. 63-97). New York: Wiley-Liss.

    Cella, D., & Bonomi, A.E. (1995). Measuring QOL: 1995 update. Oncology (Huntington), 9(Suppl. 11), 47-60.

    Cella, D., & Cherin, E. (1988). Quality of life during and after cancer treatment. Comprehensive Therapy, 14(5), 69-75.

    Cella, D., & Tulsky, D. (1990). Measuring QOL today: Methodological aspects. Oncology (Huntington), 4(5), 29-38.

    Chaudhry, V., Rowinsky, E., Sartorius, S., Donehower, R., & Cornblath, D. (1994). Peripheral neuropathy from Taxol and cisplatin combination chemotherapy clinical and electrophysiological studies. Annals of Neurology, 35, 304-311.

    Connelly, E., Markman, M., Webster, K., Kennedy, A., Kulp, B., Peterson, G., et al. (1995). Three hour infusional Taxol with cisplatin in patients with gynecological cancers [Abstract]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology, 14, 777.

    DeLaPena, L., & Pyron, S. (1993). Taxol: A case report. Cancer Nursing, 16, 423-430.

    Furlong, T. (1993). Neurologic complications of immunosuppressive cancer therapy. Oncology Nursing Forum, 20, 1337-1352.

    Hay, J.W. (2002). Quality of life effects on chemotherapy-induced neuropathy in ovarian cancer [Abstract]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology, 21, 886.

    Holden, S., & Felde, F. (1987). Nursing care of the patient experiencing cisplatin-related peripheral neuropathy. Oncology Nursing Forum, 14(1), 13-19.

    Kedar, A., Cohen, M., & Freeman, A. (1978). Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum(II) treatment: A case report. Cancer Treatment Reports, 62, 819-821.

    LoMonaco, M., Milone, M., Batocchi, A., Padua, L., Restuccia, D., & Tonali, P. (1992). Cisplatin neuropathy: Clinical cycle and neurophysiological findings. Journal of Neurology, 239, 199-204.

    McGuire, D.B. (1997). Measuring pain. In M. Frank-Stromborg & S. Olsen (Eds.)Instruments for clinical health-care research (2nd ed., pp. 528-564). Sudbury, MA: Jones and Bartlett.

    McGuire, W., Hoskins, W., Brady, M., Kucera, P., Partridge, E., Look, K., et al. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine, 334, 1-6.

    McGuire, W., Rowinsky, E., Rosehshein, N., Grumbine F., Ettinger, D., Armstrong, D., et al. (1989). Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Annals of Internal Medicine, 111, 272-279.

    Mollman, J., Glover, D., Hogan, M., & Furman, R. (1988). Cisplatin neuropathy: Risk factors, prognosis, and protection by WR-2721. Cancer, 61, 2192-2195.

    Ostchega, Y., Donohue, M., & Fox, N. (1988). High-dose cisplatin-related peripheral neuropathy. Cancer Nursing, 11, 23-32.

    Piccart, M.J., Bertelsen, K., Stuart, G., James, K., Cassidy, J., Kaye, S., et al. (1997). Is cisplatin-paclitaxel the standard in first-line treatment of advanced ovarian cancer? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience [Abstract 1258]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology, 16, 352a.

    Piper, B., Dibble, S., Dodd, M., Weiss, M., Slaughter, R., & Paul, S. (1998). The revised Piper fatigue scale: Psychometric evaluation in women with breast cancer. Oncology Nursing Forum, 25, 677-684.

    Roelofs, R., Hrushesky, W., Rogin, J., & Rosenberg, L. (1984). Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology, 34, 934-938.

    Rowinsky, E., Eisenhauer, E.A., Chaudhry, V., Arbuck, S.G., & Donehower, R.C. (1993). Clinical toxicities encountered with paclitaxel (Taxol). Seminars in Oncology, 20(4 Suppl. 3), 1-15.

    Rowinsky, E., Onnetto, N., Cannetta, R., & Arbuck, S. (1992). Taxol: The first of the taxanes, an important new class of antitumor agents. Seminars in Oncology, 19, 646-662.

    Schipper, H. (1990). Guidelines and caveats for QOL measurement in clinical practice and research. Oncology (Huntington), 4(5), 51-57.

    Smith, E.L, Whedon, M.B., & Bookbinder, M. (2002). Quality improvement of painful peripheral neuropathy. Seminars in Oncology Nursing, 18, 36-43.

    Walker, F. (1993). Paclitaxel (Taxol): Side effects and patient education issues. Seminars in Oncology Nursing, 9(4 Suppl. 2), 6-10.